UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2019-01, Vol.57 (1), p.27

2019

Volltextzugriff (PDF)

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10984-10993

2014

Volltextzugriff (PDF)

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Volltextzugriff (PDF)

CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy

Hepatology (Baltimore, Md.), 2006-04, Vol.43 (4), p.879; author reply 879-879

2006

Volltextzugriff (PDF)

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Volltextzugriff (PDF)

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

World journal of gastroenterology : WJG, 2012-03, Vol.18 (12), p.1339-1347

Claus Niederau Dietrich Huppe EImar Zehnter Bernd Moiler, Renate Heyne Stefan Christensen Rainer Waft Arno Theilmeier Ulrich Alshuth Stefan Mauss

2012

Volltextzugriff (PDF)

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Volltextzugriff (PDF)

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Hepatology (Baltimore, Md.), 2004-12, Vol.40 (6), p.1421-1425

2004

Volltextzugriff (PDF)

Current recommendations for the treatment of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2014-10, Vol.52 (10), p.1185

2014

Volltextzugriff (PDF)

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

Hepatology (Baltimore, Md.), 2004-02, Vol.39 (2), p.311-317

2004

Volltextzugriff (PDF)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3061-3071

2016

Volltextzugriff (PDF)

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

Journal of gastrointestinal and liver diseases : JGLD, 2016-03, Vol.25 (1), p.15-24

2016

Volltextzugriff (PDF)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

Annals of gastroenterology, 2017, Vol.30 (3), p.327-343

2017

Volltextzugriff (PDF)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Volltextzugriff (PDF)

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

Journal of viral hepatitis, 2011-04, Vol.18 (4), p.e81-e90

2011

Volltextzugriff (PDF)

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Volltextzugriff (PDF)

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Zeitschrift fur Gastroenterologie, 2019-05, Vol.57 (5), p.584

2019

Volltextzugriff (PDF)

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Zeitschrift fur Gastroenterologie, 2021-03, Vol.59 (3), p.241

2021

Volltextzugriff (PDF)

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2155-2163

2013

Volltextzugriff (PDF)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2143-2154

2013

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Liver international, 2021-05, Vol.41 (5), p.949-955

2021

Volltextzugriff (PDF)

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionTaylor & Francis:Master (3349 titles)

ThemaGastroenterology & Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(42)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Humans
(28)
Male
(20)
Female
(19)
Hepatitis C
(19)
Middle Aged
(17)
Antiviral Agents - Therapeutic Use
(16)
Adult
(15)
Hepatitis
(13)
Hepatitis C, Chronic - Drug Therapy
(13)
Patients
(11)
Drug Therapy, Combination
(10)
Germany
(10)
Treatment Outcome
(10)
Cirrhosis
(8)
Hepacivirus - Genetics
(8)
Hepatitis C - Drug Therapy
(8)
Infectious Diseases
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Current recommendations for the treatment of chronic hepatitis C

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Aktive Filter

Suchergebnisse filtern